GHRP-2 GR2
GHS-R1a agonist
Synthetic hexapeptide (pralmorelin) that activates the ghrelin receptor GHS-R1a and stimulates pituitary growth hormone release.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- GHS-R1a agonist
- Category
- Growth Hormone Axis
- Type
- Single compound
- Abbreviation
- GR2
- Development and regulatory status
- Approved in Japan as diagnostic agent only; research compound elsewhere
What researchers study
Synthetic hexapeptide (pralmorelin) that activates the ghrelin receptor GHS-R1a, stimulating pituitary growth hormone release. It also raises food intake and has been used as a diagnostic stimulus of GH secretion.
Research areas
- Ghrelin-receptor and GH release studies
- Diagnostic GH-stimulation test development
- Food-intake and appetite regulation in humans
- Livestock growth-axis studies
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- human trial
In 19 healthy lean and obese adults, GHRP-2 infusion raised ad libitum food intake dose-dependently, by 10.2% and 33.5% at two infusion levels versus placebo
- review
As a diagnostic stimulus, GHRP-2 markedly raised GH in healthy subjects but significantly less in people with GH deficiency
- livestock
In yaks with growth retardation, GHRP-2 was associated with faster growth and higher GH and IGF-1 secretion
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- GHRP-2 Acetateacetate salt form of the same peptide
- GHRP-6related ghrelin-receptor agonist compared in GH and appetite studies
- CJC-1295 (no DAC)GHRH analogue acting synergistically with ghrelin-receptor agonists
- SermorelinGHRH(1-29) analogue acting through the complementary receptor
